GSK plc (NYSE:GSK) Position Lessened by SG Americas Securities LLC

SG Americas Securities LLC decreased its stake in GSK plc (NYSE:GSK) by 41.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,991 shares of the pharmaceutical company’s stock after selling 7,782 shares during the period. SG Americas Securities LLC’s holdings in GSK were worth $372,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. FMR LLC increased its position in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its stake in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Primecap Management Co. CA boosted its position in shares of GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after buying an additional 342,365 shares during the period. Provident Trust Co. boosted its position in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after buying an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its position in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the period. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GSK. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $34.91 on Tuesday. The stock has a market cap of $72.34 billion, a P/E ratio of 22.67, a P/E/G ratio of 1.38 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a fifty day moving average price of $34.07 and a two-hundred day moving average price of $37.67. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.